Phase 3 N=346 Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies
Tumor Lysis Syndrome
Primary: Serum Uric Acid (sUA) Level Control — 514.0; 708.0 mg x hour/dL — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=80 Rasburicase in Patients at Risk for Tumor Lysis Syndrome
Tumor Lysis Syndrome
Primary: Number of Participants With Plasma Uric Acid (UA) Response — 39; 34 participants
Phase 2 N=55 Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2
Leukemia · Lymphoma
Primary: Number of Participants (Incidence) of LTLS (Laboratory Tumor Lysis Syndrome) — 1; 1 Participants
Phase 3 N=280 Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome
Tumor Lysis Syndrome · Cancer · Hyperuricemia
Primary: Plasma Uric Acid Responder — 80; 72; 60; 12 Participants — p=0.0009
Phase 2 N=17 LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma
Non-Hodgkin's Lymphoma
Primary: Complete Remission — 10 participants
Phase 2 N=142 ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas
Solid Tumor · Lymphoma · Peripheral T-Cell Lymphoma
Primary: Evaluate the Safety and Tolerability of ALRN-6924 in Adult Patients With Advanced Solid Tumors or Lymphomas With Wild-type (WT) TP53 Who Are Refractory to or Intolerant…
N/A N=3,800 Liver Function Test (LFT) Elevations in Cancer Patients and Users of Tyrosine Kinase Inhibitor (TKI) Drugs
Cancer
Primary: Number of Patients With ALT (Alanine Transaminase) >=3x (Times) Upper Limit of Normal (ULN) — 11 participants
Phase 1 N=9 Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma
Sarcoma
Primary: Number of Participants Who Experienced Serious Adverse Events and Adverse Events — 4; 5 Participants
Phase 2 N=97 Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma
Childhood Burkitt Lymphoma · Childhood Diffuse Large Cell Lymphoma · Childhood Immunoblastic Large Cell Lymphoma
Primary: Grade ≥ 3 Stomatitis — 4; 6; 41; 34 participants
Phase 3 N=1,895 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
T Acute Lymphoblastic Leukemia · T Lymphoblastic Lymphoma
Primary: Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV) — 89.01; 90.53; 78.07; 86.46 percent probability
Phase 1 N=5 TIL Therapy for Metastatic Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Primary: Number of Patients in Which the Treatment Was Tolerable — 5 Participants
Phase 1 N=12 A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients
T Cell Lymphoma
Primary: Overall Response Rate — 5 participants
Phase 2 N=4 Lenalidomide in HTLV-1 Adult T-Cell Leukemia
Adult T Cell Leukemia/Lymphoma
Primary: Response Rate (CR + Cru + PR)
Phase 2 N=25 Phase 2 Study of Atorvastatin Safety and Antitumor Effects in Non-Hodgkin's Lymphoma
Leukemia · Lymphoma, Non-Hodgkin
Primary: Tumor Apoptosis — 7 Participants
Phase 3 N=271 Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Relapsed Peripheral T-Cell Lymphoma · Refractory Peripheral T-Cell Lymphoma
Primary: Overall Response Rate (ORR) Based on Independent Review Committee (IRC) Assessment — 33; 45 percentage of participants — p=0.038
Phase 1 N=40 LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
Hodgkin Disease · Non Hodgkin Lymphoma · Lymphoepithelioma
Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…
Phase 3 N=47 Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL
Acute Lymphoblastic Leukemia (ALL)
Primary: Number of Participants With Adverse Event to HD-MTX Treatment in NOPHO ALL-2008 as a Measure of Toxic Mtx Concentrations in Blood, Nephrotoxicity, Hepatotoxicity…
Phase 2 N=6 LTX-315 and Adoptive T-cell Therapy in Advanced Soft Tissue Sarcoma (ATLAS-IT-04)
Soft Tissue Sarcoma
Primary: Change in Total T-cell Level in Tumour Tissues From Baseline (Step 1, Week 1, Day 1) to End of Step 1 (Step 1, Week 3-5) — 1.9 factor change in cells/mm2
Phase 2 N=42 Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma
Adult Nasal Type Extranodal NK/T-Cell Lymphoma · Anaplastic Large Cell Lymphoma · Angioimmunoblastic T-Cell Lymphoma
Primary: Objective Response Rate (Complete Responses (CR) + Partial Responses (PR)) — 2; 7; 28 participants
Phase 2 N=96 Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia
Accelerated Phase Chronic Myelogenous Leukemia · Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Myeloid Leukemia in Remission
Primary: Relapse Incidence — 18 Participants
Phase 2 N=66 Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions
Multiple Myeloma
Primary: Proportion of Participants With Relapsed Multiple Myeloma With Progression-free (PFS) — 0.31 Proportion of participants PFS
Phase 2 N=23 Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients
Thrombotic Microangiopathies · Atypical Hemolytic Uremic Syndrome · Multiple Organ Dysfunction Syndrome
Primary: Survival — 15 Participants — p=<0.0001
Phase 2 N=18 Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia
Adult T-Cell Leukemia (ATL)
Primary: Percentage of Participants With a Minimally Durable Clinical Response Rate — 80; 0; 60; 0 percentage of participants
Phase 2 N=13 Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas
Lymphoma, T-Cell
Primary: Objective Response Rate — 8 percentage of patients
Phase 2 N=48 Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL
Leukemia
Primary: Maximum Tolerated Dose (MTD) Oxaliplatin — 25 mg/m^2
N/A N=8 Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation
Leukemia, Myeloid, Acute · Leukemia, Lymphoblastic, Acute · Leukemia, Myelocytic, Chronic
Primary: Overall Recipient Survival at 6-month Post-relapse of Disease — 0; 4 participants
Phase 2 N=29 Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia
T-LGL Lymphoproliferative Disorders
Primary: Number of Participants With Hematological Response After Three Months of Alemtuzumab — 15 Participants
Phase 1 N=46 Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Chronic Myeloproliferative Disorders · Graft Versus Host Disease · Leukemia
Primary: Percentage of Participants With Grades II to IV Acute Graft-Versus-Host Disease (aGVHD) — 24; 57 percentage of participants — p=.036
Phase 2 N=23 NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma
Lymphoblastic Lymphoma
Primary: Probability of Event-free Survival (EFS) — 91.7; 71.4; 100; 86.96 percentage of event-free patients
Phase 2 N=3 Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
Acute Adult T-Cell Leukemia/Lymphoma · Adult T-Cell Leukemia/Lymphoma · Chronic Adult T-Cell Leukemia/Lymphoma
Primary: Incidence of Adverse Events of Nivolumab, Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 — 3 Participants